BioMed X, a leading innovation hub for pharma,announced the start of a new research team at its Heidelberg institute for multispecific biologics in the field of immuno-oncology in collaboration with Daiichi Sankyo (TSE: 4568) through its Daiichi Sankyo Research Institute in Munich. This new project, led by BioMed X boot camp winner Dr. Reda Benmebarek, will explore next-generation biologics as a potential strategy to transform how solid tumors are treated.

“The ability of multispecific biologics to engage multiple targets simultaneously represents a powerful strategy to overcome the limitations of conventional therapies,” explains Dr. Reda Benmebarek. “By targeting the microenvironment with new biologic scaffolds, we aim to simultaneously recruit immune cells and activate potent immune responses that could potentially increase the efficacy of solid tumor therapy.”

Before joining BioMed X as a group leader, Dr. Benmebarek was a post-doctoral fellow at the National Institutes of Health (NIH) in Bethesda, Maryland, USA, and at Ludwig-Maximilians-Universität München in Munich, Germany where his research focused on mechanisms that govern response and resistance to immunotherapeutics within the tumor microenvironment.

“We are excited to work with Daiichi Sankyo and bring together the innovative minds of both companies to improve cancer therapy,” said Dr. Thomas Rückle, Head of Research Europe at BioMed X. “This collaboration demonstrates our commitment to developing innovative multispecific platforms that may provide more effective treatment options for patients with solid tumors.”

BioMed X’s innovation model provides fertile ground for high-risk, high-reward science. With sites in Heidelberg and New Haven, and satellite research teams embedded directly within pharma R&D environments, BioMed X offers a collaborative space where top talents from academia and industry work side by side. This collaboration with Daiichi Sankyo underscores BioMed X’s role as a truly global innovation hub. By connecting leading minds from around the world, BioMed X accelerates the translation of disruptive scientific ideas into new therapeutic concepts with worldwide impact.

The new research team will join five other groups at the BioMed X Institute in Heidelberg, Germany, as well as two international teams: one at the BioMed X Institute in New Haven, Connecticut, USA and another at its XSeed Labs in Ridgefield, Connecticut, an innovation accelerator located on the campus of Boehringer Ingelheim in the USA.